Roche’s patent dispute with London-listed Shire over the Swiss drugmaker’s new hemophilia drug Hemlibra escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.
The U.S. FDA approved two doses of Pfizer Inc.’s medicine Xeljanz for treating active psoriatic arthritis.
Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated the German company’s ambitions almost seven years ago.
Revance Therapeutics Inc. will wait to seek partnerships with bigger drugmakers until the company is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.
Medtronic Plc agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said.
Impressive top-line results were reported from a pivotal Phase II study for the PD-1 inhibitor cemiplimab.
Allergan is buying Repros Therapeutics for $0.67 per share. The deal is expected to close in the first quarter of 2018.
The FDA accepted Indivior’s application for its new once-monthly injectable schizophrenia treatment.
The U.S. Food and Drug Administration approved Sanofi SA’s Admelog as the first follow-on biologic version of Eli Lilly and Co.’s fast-acting insulin Humalog.
At the American Society of Hematology meeting, Genentech revealed long-term data showing the drug maintains its efficacy over an extended period of time.